The new era of trabectedin in soft tissue sarcomas

Axel Le Cesne; Julien Domont; Angela Cioffi

The new era of trabectedin in soft tissue sarcomas

Axel Le Cesne, Julien Domont, Angela Cioffi

Résultats de recherche: Contribution à un journal › Brève enquête › Revue par des pairs

Résumé

Prognosis for patients with soft tissue sarcomas remains poor and pharmaceutical research in this area is limited. Therefore the regulatory approval of trabectedin for the treatment of adult soft tissue sarcomas is an important milestone.

langue originale	Anglais
Pages (de - à)	17-20
Nombre de pages	4
journal	European Journal of Oncology Pharmacy
Volume	2
Numéro de publication	2
état	Publié - 1 déc. 2008

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{7f0c9c04b7a5476d941691a1a313a55c,

title = "The new era of trabectedin in soft tissue sarcomas",

abstract = "Prognosis for patients with soft tissue sarcomas remains poor and pharmaceutical research in this area is limited. Therefore the regulatory approval of trabectedin for the treatment of adult soft tissue sarcomas is an important milestone.",

author = "{Le Cesne}, Axel and Julien Domont and Angela Cioffi",

year = "2008",

month = dec,

day = "1",

language = "English",

volume = "2",

pages = "17--20",

journal = "European Journal of Oncology Pharmacy",

issn = "1783-3914",

number = "2",

}

TY - JOUR

T1 - The new era of trabectedin in soft tissue sarcomas

AU - Le Cesne, Axel

AU - Domont, Julien

AU - Cioffi, Angela

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Prognosis for patients with soft tissue sarcomas remains poor and pharmaceutical research in this area is limited. Therefore the regulatory approval of trabectedin for the treatment of adult soft tissue sarcomas is an important milestone.

AB - Prognosis for patients with soft tissue sarcomas remains poor and pharmaceutical research in this area is limited. Therefore the regulatory approval of trabectedin for the treatment of adult soft tissue sarcomas is an important milestone.

UR - http://www.scopus.com/inward/record.url?scp=77953462091&partnerID=8YFLogxK

M3 - Short survey

AN - SCOPUS:77953462091

SN - 1783-3914

VL - 2

SP - 17

EP - 20

JO - European Journal of Oncology Pharmacy

JF - European Journal of Oncology Pharmacy

IS - 2

ER -